Nelson Vergel
Founder, ExcelMale.com
Curated by Nelson Vergel | ExcelMale.com | Updated June 2026
Female sexual dysfunction is one of the most common and least treated conditions in medicine. Roughly 43% of women report sexual symptoms at some point, but the clinical threshold for dysfunction is narrower: about 12% meet diagnostic criteria, defined by the presence of marked personal distress. The condition peaks in the 45-to-64 age range -- not because those women want less, but because the hormonal shifts of menopause, the psychological weight of midlife, and years of inadequate clinical attention tend to converge at once.
For decades, women dealing with low desire, painful sex, or arousal problems had almost no medical options. That has changed. Two FDA-approved drugs now directly target the neurochemistry of desire. A global consensus from 11 major medical societies backs testosterone therapy for postmenopausal women. Local hormonal treatments can reverse the tissue changes of menopause safely and effectively. This guide covers the current clinical toolkit -- what each treatment targets, who qualifies, and what the evidence shows.
Not every shift in sexual interest is a medical problem. The defining requirement is personal distress. Research shows that while 43.1% of women report sexual symptoms, only 22.2% experience distress from them -- and roughly 12% meet the clinical threshold for FSD [1]. Without distress, a change in sexual function is a normal variation, not a disorder. This distinction matters clinically because it protects women from unnecessary treatment while directing resources toward those who genuinely need help.
The two most significant clinical presentations are:
Hypoactive Sexual Desire Disorder (HSDD): a persistent absence of sexual thoughts, fantasies, or desire that causes marked distress. HSDD is the most common female sexual complaint, affecting roughly 10% of all women and up to 28% of premenopausal women with any reported sexual dysfunction.
Genitourinary Syndrome of Menopause (GSM): the physical changes in vaginal and urinary tissue that follow estrogen and androgen withdrawal -- dryness, tissue thinning, painful intercourse (dyspareunia), and urinary urgency. GSM affects up to 60% of postmenopausal women, yet most never seek treatment because they assume pain and dryness are simply part of aging.
The two conditions often co-occur. GSM creates a pain response that trains the brain to associate sex with discomfort, which suppresses desire. That cycle can become self-reinforcing if neither condition is treated.
At the neurochemical level, HSDD reflects an imbalance between excitatory signals -- dopamine, norepinephrine, and melanocortins -- that push toward desire, and inhibitory signals, primarily serotonin, that work against it. Treatment either strengthens the excitatory side, reduces inhibition, or addresses the hormonal environment that primes these circuits [2].
Two medications are currently FDA-approved specifically for HSDD. Both target the neurochemical balance described above, but they work differently and suit different patient profiles.
Flibanserin is a 5-HT1A agonist and 5-HT2A antagonist. In practical terms, it reduces inhibitory serotonin signaling while raising dopamine and norepinephrine. It was originally studied as an antidepressant before researchers noticed its effect on desire. The FDA approved it in 2015 for premenopausal women; in 2025, the approval was expanded to include postmenopausal women up to age 65.
Dosing: 100 mg taken orally at bedtime, daily. Effects require several weeks of consistent use. This is not an on-demand treatment.
Phase III trials showed flibanserin increased satisfying sexual events by roughly 0.5 to 1 per month versus placebo, with meaningful improvements in desire scores [3]. The effect size is modest and has been debated since approval. That said, improvements in this domain -- even small ones -- often matter a great deal to the women experiencing them.
The primary safety concern is alcohol interaction. Flibanserin combined with alcohol can cause significant hypotension and syncope. CYP3A4 inhibitors (certain antibiotics, antifungals, and other common drugs) raise flibanserin blood levels substantially and must be avoided. Prescribers must complete an FDA certification before prescribing.
Bremelanotide takes a different approach. It binds MC4R receptors in the hypothalamus, triggering presynaptic dopamine release. The FDA approved it in 2019 for premenopausal women with HSDD. Unlike flibanserin, it is used on demand -- injected subcutaneously roughly 45 minutes before anticipated sexual activity.
Dosing: 1.75 mg subcutaneous injection, no more than one dose per day and no more than eight doses per month.
The RECONNECT trials showed statistically significant improvements in sexual desire and reductions in distress versus placebo -- about 25% of women reported meaningful desire improvement compared to 17% with placebo [4]. Nausea affects roughly 10% of users and is the most common reason for discontinuation; flushing and headache also occur. The injection format suits women who prefer not to commit to a daily medication, though the self-injection requirement is a practical barrier for some.
The idea that testosterone is exclusively a male hormone is both outdated and clinically harmful. Women produce testosterone in the ovaries and adrenal glands -- at roughly 5-10% of male concentrations -- and it plays a direct role in sexual motivation, clitoral circulation, genital tissue maintenance, and the brain's excitatory priming for desire.
When postmenopausal women with HSDD are evaluated, low testosterone is frequently part of the picture. The evidence base for treating it is substantial enough that a joint position statement from 11 major medical societies -- including the Endocrine Society, the International Menopause Society, and the International Society for Sexual Medicine -- endorsed transdermal testosterone as the evidence-based treatment for postmenopausal HSDD [5]. This is one of the more decisive clinical consensus statements in women's sexual health.
The recommended dose is 300 mcg per 24 hours via patch or cream, approximating normal premenopausal female testosterone concentrations. Monitoring targets are 60-120 ng/dL total testosterone. The practical goal is physiological premenopausal levels -- not male levels.
The regulatory situation is genuinely frustrating. There is no FDA-approved testosterone product formulated specifically for women in the United States. Clinicians typically use male-formulated 1% testosterone cream at reduced doses, or work with compounding pharmacies. Androfeme (1% testosterone cream for women) is approved and widely used in Australia and is the most studied formulation in female HSDD trials -- but it is not available in the US.
For women in their late reproductive years (perimenopausal), limited evidence also supports testosterone use when total testosterone is documented as low alongside HSDD symptoms, consistent with ISSWSH guidelines [6]. This is still off-label, but it is increasingly common in sexual medicine practice.
Side effects at physiological doses are generally mild. Some women notice mild acne or slightly increased body hair, particularly if dosing drifts above physiological range. The global consensus statement found no serious adverse events at physiologic doses across randomized trials lasting up to 24 months [5].
It does, and this point is underemphasized in most clinical discussions.
Oral estrogen stimulates the liver to produce sex hormone-binding globulin (SHBG). SHBG binds testosterone in the bloodstream, reducing the fraction of free, biologically active testosterone available to tissues. A woman who starts oral estrogen for hot flashes may see her free testosterone drop -- not because she is producing less testosterone, but because her SHBG is now sequestering more of it. The downstream effect can be a significant loss of desire, even when total testosterone looks normal on a lab report.
Transdermal estradiol -- patches, gels, or sprays applied to the skin -- bypasses the liver's first-pass metabolism and raises SHBG far less. For postmenopausal women who need hormonal support and want to preserve sexual function, the route of estrogen delivery is a meaningful clinical choice [7].
This also has direct implications for interpreting testosterone lab results. A woman on oral estrogen with a "normal" total testosterone may actually have suppressed free testosterone. A complete hormonal assessment should include either free testosterone or SHBG -- not just total testosterone. The ExcelMale community has documented this SHBG dynamic extensively in men on TRT, and the same mechanism applies to women on oral estrogen.
Treating GSM is not optional for women who want to address their libido. Pain during intercourse that goes untreated will continue to suppress desire. The treatments below address tissue health directly and consistently outperform lubricants and moisturizers in clinical trials for moderate to severe symptoms.
Low-dose vaginal estrogen remains the most effective treatment for GSM. Studies confirm that low-dose vaginal estrogen does not raise circulating estradiol above postmenopausal ranges, which has improved its safety profile even for women with certain cancer histories. Local estrogen is now included in urological guidelines as a preventive strategy for recurrent urinary tract infections -- a benefit that underscores how systemic the consequences of urogenital tissue atrophy really are.
Vaginal DHEA (prasterone) was approved by the FDA in 2016 for dyspareunia associated with menopause. The nightly 6.5 mg insert works via intracrinology: vaginal cells themselves convert the inactive DHEA precursor into both estrogens and androgens locally, restoring tissue health without meaningfully raising systemic hormone levels [8]. Phase III trials showed clinically and statistically significant improvements in dyspareunia, vaginal dryness, and tissue quality with daily use.
For breast cancer survivors on aromatase inhibitors -- who cannot use any form of systemic or local estrogen -- vaginal DHEA is particularly valuable. Small studies show that serum estradiol remains within normal postmenopausal ranges throughout treatment, with meaningful improvements in painful sex and sexual function scores [9].
Ospemifene is a selective estrogen receptor modulator (SERM) taken orally at 60 mg daily. It acts as an estrogen agonist on vaginal tissue while avoiding uterine stimulation. For women who cannot tolerate vaginal application or who decline it, ospemifene is a well-studied alternative for dyspareunia. It is the only oral non-estrogen option in this category.
Given the limits of the approved toolkit -- particularly the gap between what postmenopausal women need and what exists in FDA-approved form -- sexual medicine specialists routinely use compounded formulations and off-label combinations. The evidence base for these is generally smaller, but clinical experience is accumulating.
Several compounding pharmacies, including Empower Pharmacy, produce a topical cream applied to the clitoris containing testosterone alongside up to six prescription vasodilators -- typically including sildenafil, alprostadil, and L-arginine. The goal is to increase local blood flow, clitoral engorgement, and sensitivity. The ExcelMale community has discussed this formulation for years; clinicians who prescribe it report consistent positive patient feedback.
One practical note: the testosterone component works best when baseline androgen levels are already in range. Women with documented androgen insufficiency may see better results after their systemic levels are corrected first. Testing free testosterone and SHBG before or alongside prescribing makes clinical sense.
These targeted oral combinations are designed around phenotyping women by their inhibitory profile:
Both remain investigational in the US. The phenotyping science behind them is well-grounded; commercial availability is the bottleneck.
Bupropion and buspirone are used off-label for HSDD, particularly in women experiencing SSRI-induced sexual dysfunction. Bupropion inhibits dopamine and norepinephrine reuptake, pressing the excitatory accelerator. Clinical evidence is less robust than for flibanserin or bremelanotide, but both are widely used in psychiatric-sexual medicine practice. Lorexys -- a combination of bupropion and trazodone -- is currently under investigation as a more targeted formulation for this indication [2].
Sildenafil and tadalafil have a narrower application in women -- primarily in arousal disorders tied to diabetes or antidepressant use, where the primary problem is genital blood flow rather than central desire. The disconnect between genital engorgement and subjective desire is well-documented; improving vascular response alone does not always translate into increased desire. These agents work best when the central excitatory system is already primed but peripheral response is mechanically impaired.
Yes, and this is one of the most under-discussed drivers of low desire in younger women. Combined oral contraceptives raise SHBG significantly, binding more free testosterone. Some women in their 20s test with single-digit testosterone levels as a direct result. If low libido develops after starting hormonal contraception, measuring free testosterone and SHBG is worthwhile. Switching to a progestin-only method, IUD, or non-hormonal contraception often reverses the effect.
This is still an evolving area. Small studies suggest vaginal testosterone and vaginal DHEA are viable options for breast cancer survivors on aromatase inhibitors, since local tissue conversion does not meaningfully raise circulating estradiol. Systemic testosterone in women with hormone-receptor-positive breast cancer history requires careful discussion with the oncologist; it is not supported by major guidelines at this time, and data remain limited.
Flibanserin typically requires 4-8 weeks of consistent nightly use before effects become apparent -- it is not a situational drug. Transdermal testosterone in postmenopausal women generally shows meaningful improvement in desire and satisfying sexual events within 12-24 weeks, with continued improvement out to 52 weeks in longer trials. Local estrogen therapy for GSM often shows tissue changes within 4-8 weeks, though dyspareunia improvements can take longer.
Most sexual medicine specialists recommend at least brief psychosexual counseling alongside pharmacotherapy, particularly when relationship dynamics, mood disorders, or a history of trauma are part of the picture. Medication adjusts the neurochemistry; it cannot fix communication gaps or relationship dissatisfaction. The biopsychosocial model exists because biology is only one of three contributing factors. Women with situational HSDD -- present only with a specific partner or in specific contexts -- are more likely to benefit from counseling-led approaches than pharmacotherapy alone.
Four questions are worth raising: What specifically is driving my symptoms -- hormonal, structural, psychological, or a combination? Have my free testosterone and SHBG been measured, not just total testosterone? If I'm on oral estrogen, have we discussed switching to transdermal? And if the first treatment does not work after a reasonable trial, what is the next step in the clinical plan?
One thing most hormonal health discussions leave out: the relationship between oral estrogen, SHBG, and testosterone suppression is probably responsible for more undiagnosed low desire in midlife women than any other single factor. A woman can be on hormone replacement, have a "normal" total testosterone result, and still have essentially no free testosterone available to her tissues -- all because the oral estrogen she is taking is driving SHBG up. Switching to transdermal estrogen costs nothing and often changes everything.
The pharmacological toolkit for female sexual dysfunction has expanded meaningfully in the past decade. The gaps are real -- no FDA-approved testosterone product for women, limited options for postmenopausal HSDD that are not off-label -- but the clinical evidence base has never been stronger. Women deserve the same level of attention to sexual health that men have received for 30 years.
For further reading, see our guides on Testosterone and Menopause and Testosterone Myths, Benefits, and Risks of HRT After Menopause.
ExcelMale.com is a men's health forum and educational resource founded by Nelson Vergel, a chemical engineer, long-term TRT patient, and author of Testosterone: A Man's Guide and Beyond Testosterone. With more than 24,000 members and 20+ years of forum archives, ExcelMale provides evidence-based information on testosterone replacement therapy, hormone optimization, sexual health, and related topics for both men and women. Nelson is a recognized patient advocate with over 34 years of personal experience on TRT.
Female sexual dysfunction is one of the most common and least treated conditions in medicine. Roughly 43% of women report sexual symptoms at some point, but the clinical threshold for dysfunction is narrower: about 12% meet diagnostic criteria, defined by the presence of marked personal distress. The condition peaks in the 45-to-64 age range -- not because those women want less, but because the hormonal shifts of menopause, the psychological weight of midlife, and years of inadequate clinical attention tend to converge at once.
For decades, women dealing with low desire, painful sex, or arousal problems had almost no medical options. That has changed. Two FDA-approved drugs now directly target the neurochemistry of desire. A global consensus from 11 major medical societies backs testosterone therapy for postmenopausal women. Local hormonal treatments can reverse the tissue changes of menopause safely and effectively. This guide covers the current clinical toolkit -- what each treatment targets, who qualifies, and what the evidence shows.
What Is Female Sexual Dysfunction and When Does It Require Treatment?
Not every shift in sexual interest is a medical problem. The defining requirement is personal distress. Research shows that while 43.1% of women report sexual symptoms, only 22.2% experience distress from them -- and roughly 12% meet the clinical threshold for FSD [1]. Without distress, a change in sexual function is a normal variation, not a disorder. This distinction matters clinically because it protects women from unnecessary treatment while directing resources toward those who genuinely need help.
The two most significant clinical presentations are:
Hypoactive Sexual Desire Disorder (HSDD): a persistent absence of sexual thoughts, fantasies, or desire that causes marked distress. HSDD is the most common female sexual complaint, affecting roughly 10% of all women and up to 28% of premenopausal women with any reported sexual dysfunction.
Genitourinary Syndrome of Menopause (GSM): the physical changes in vaginal and urinary tissue that follow estrogen and androgen withdrawal -- dryness, tissue thinning, painful intercourse (dyspareunia), and urinary urgency. GSM affects up to 60% of postmenopausal women, yet most never seek treatment because they assume pain and dryness are simply part of aging.
The two conditions often co-occur. GSM creates a pain response that trains the brain to associate sex with discomfort, which suppresses desire. That cycle can become self-reinforcing if neither condition is treated.
At the neurochemical level, HSDD reflects an imbalance between excitatory signals -- dopamine, norepinephrine, and melanocortins -- that push toward desire, and inhibitory signals, primarily serotonin, that work against it. Treatment either strengthens the excitatory side, reduces inhibition, or addresses the hormonal environment that primes these circuits [2].
What FDA-Approved Medications Treat Low Libido in Women?
Two medications are currently FDA-approved specifically for HSDD. Both target the neurochemical balance described above, but they work differently and suit different patient profiles.
Flibanserin (Addyi): A Daily CNS Recalibrator
Flibanserin is a 5-HT1A agonist and 5-HT2A antagonist. In practical terms, it reduces inhibitory serotonin signaling while raising dopamine and norepinephrine. It was originally studied as an antidepressant before researchers noticed its effect on desire. The FDA approved it in 2015 for premenopausal women; in 2025, the approval was expanded to include postmenopausal women up to age 65.
Dosing: 100 mg taken orally at bedtime, daily. Effects require several weeks of consistent use. This is not an on-demand treatment.
Phase III trials showed flibanserin increased satisfying sexual events by roughly 0.5 to 1 per month versus placebo, with meaningful improvements in desire scores [3]. The effect size is modest and has been debated since approval. That said, improvements in this domain -- even small ones -- often matter a great deal to the women experiencing them.
The primary safety concern is alcohol interaction. Flibanserin combined with alcohol can cause significant hypotension and syncope. CYP3A4 inhibitors (certain antibiotics, antifungals, and other common drugs) raise flibanserin blood levels substantially and must be avoided. Prescribers must complete an FDA certification before prescribing.
Bremelanotide (Vyleesi): An On-Demand Melanocortin Agonist
Bremelanotide takes a different approach. It binds MC4R receptors in the hypothalamus, triggering presynaptic dopamine release. The FDA approved it in 2019 for premenopausal women with HSDD. Unlike flibanserin, it is used on demand -- injected subcutaneously roughly 45 minutes before anticipated sexual activity.
Dosing: 1.75 mg subcutaneous injection, no more than one dose per day and no more than eight doses per month.
The RECONNECT trials showed statistically significant improvements in sexual desire and reductions in distress versus placebo -- about 25% of women reported meaningful desire improvement compared to 17% with placebo [4]. Nausea affects roughly 10% of users and is the most common reason for discontinuation; flushing and headache also occur. The injection format suits women who prefer not to commit to a daily medication, though the self-injection requirement is a practical barrier for some.
Why Does Testosterone Matter for Women's Sexual Health?
The idea that testosterone is exclusively a male hormone is both outdated and clinically harmful. Women produce testosterone in the ovaries and adrenal glands -- at roughly 5-10% of male concentrations -- and it plays a direct role in sexual motivation, clitoral circulation, genital tissue maintenance, and the brain's excitatory priming for desire.
When postmenopausal women with HSDD are evaluated, low testosterone is frequently part of the picture. The evidence base for treating it is substantial enough that a joint position statement from 11 major medical societies -- including the Endocrine Society, the International Menopause Society, and the International Society for Sexual Medicine -- endorsed transdermal testosterone as the evidence-based treatment for postmenopausal HSDD [5]. This is one of the more decisive clinical consensus statements in women's sexual health.
The recommended dose is 300 mcg per 24 hours via patch or cream, approximating normal premenopausal female testosterone concentrations. Monitoring targets are 60-120 ng/dL total testosterone. The practical goal is physiological premenopausal levels -- not male levels.
The regulatory situation is genuinely frustrating. There is no FDA-approved testosterone product formulated specifically for women in the United States. Clinicians typically use male-formulated 1% testosterone cream at reduced doses, or work with compounding pharmacies. Androfeme (1% testosterone cream for women) is approved and widely used in Australia and is the most studied formulation in female HSDD trials -- but it is not available in the US.
For women in their late reproductive years (perimenopausal), limited evidence also supports testosterone use when total testosterone is documented as low alongside HSDD symptoms, consistent with ISSWSH guidelines [6]. This is still off-label, but it is increasingly common in sexual medicine practice.
Side effects at physiological doses are generally mild. Some women notice mild acne or slightly increased body hair, particularly if dosing drifts above physiological range. The global consensus statement found no serious adverse events at physiologic doses across randomized trials lasting up to 24 months [5].
Does the Type of Estrogen Therapy Affect Testosterone Levels and Libido?
It does, and this point is underemphasized in most clinical discussions.
Oral estrogen stimulates the liver to produce sex hormone-binding globulin (SHBG). SHBG binds testosterone in the bloodstream, reducing the fraction of free, biologically active testosterone available to tissues. A woman who starts oral estrogen for hot flashes may see her free testosterone drop -- not because she is producing less testosterone, but because her SHBG is now sequestering more of it. The downstream effect can be a significant loss of desire, even when total testosterone looks normal on a lab report.
Transdermal estradiol -- patches, gels, or sprays applied to the skin -- bypasses the liver's first-pass metabolism and raises SHBG far less. For postmenopausal women who need hormonal support and want to preserve sexual function, the route of estrogen delivery is a meaningful clinical choice [7].
This also has direct implications for interpreting testosterone lab results. A woman on oral estrogen with a "normal" total testosterone may actually have suppressed free testosterone. A complete hormonal assessment should include either free testosterone or SHBG -- not just total testosterone. The ExcelMale community has documented this SHBG dynamic extensively in men on TRT, and the same mechanism applies to women on oral estrogen.
What Treatments Work for Painful Sex and GSM After Menopause?
Treating GSM is not optional for women who want to address their libido. Pain during intercourse that goes untreated will continue to suppress desire. The treatments below address tissue health directly and consistently outperform lubricants and moisturizers in clinical trials for moderate to severe symptoms.
| Treatment | Delivery | Primary Use | Notes |
|---|---|---|---|
| Local Estrogen Therapy (LET) | Cream, ring, or tablet (vaginal) | Dryness, dyspareunia, UTI prevention | Minimal systemic absorption; evidence-based first-line |
| Vaginal DHEA / Prasterone (Intrarosa) | Nightly vaginal insert (6.5 mg) | Dyspareunia, tissue restoration | Works via intracrinology; safe for aromatase inhibitor users |
| Ospemifene (Osphena) | Oral tablet (60 mg daily) | Dyspareunia, vaginal atrophy | SERM; estrogen-agonist effect on vaginal tissue only |
| Vaginal Testosterone | Compounded cream | GSM in breast cancer survivors on AIs | Local effect; minimal systemic aromatization |
| Fractional CO2 Laser | Energy-based device | Tissue remodeling, symptom relief | Adjunct; less evidence than hormonal options |
Local Estrogen Therapy (LET)
Low-dose vaginal estrogen remains the most effective treatment for GSM. Studies confirm that low-dose vaginal estrogen does not raise circulating estradiol above postmenopausal ranges, which has improved its safety profile even for women with certain cancer histories. Local estrogen is now included in urological guidelines as a preventive strategy for recurrent urinary tract infections -- a benefit that underscores how systemic the consequences of urogenital tissue atrophy really are.
Vaginal DHEA (Prasterone / Intrarosa)
Vaginal DHEA (prasterone) was approved by the FDA in 2016 for dyspareunia associated with menopause. The nightly 6.5 mg insert works via intracrinology: vaginal cells themselves convert the inactive DHEA precursor into both estrogens and androgens locally, restoring tissue health without meaningfully raising systemic hormone levels [8]. Phase III trials showed clinically and statistically significant improvements in dyspareunia, vaginal dryness, and tissue quality with daily use.
For breast cancer survivors on aromatase inhibitors -- who cannot use any form of systemic or local estrogen -- vaginal DHEA is particularly valuable. Small studies show that serum estradiol remains within normal postmenopausal ranges throughout treatment, with meaningful improvements in painful sex and sexual function scores [9].
Ospemifene (Osphena)
Ospemifene is a selective estrogen receptor modulator (SERM) taken orally at 60 mg daily. It acts as an estrogen agonist on vaginal tissue while avoiding uterine stimulation. For women who cannot tolerate vaginal application or who decline it, ospemifene is a well-studied alternative for dyspareunia. It is the only oral non-estrogen option in this category.
What Compounded and Off-Label Options Are Clinicians Using?
Given the limits of the approved toolkit -- particularly the gap between what postmenopausal women need and what exists in FDA-approved form -- sexual medicine specialists routinely use compounded formulations and off-label combinations. The evidence base for these is generally smaller, but clinical experience is accumulating.
"Scream Cream" (Compounded Topical)
Several compounding pharmacies, including Empower Pharmacy, produce a topical cream applied to the clitoris containing testosterone alongside up to six prescription vasodilators -- typically including sildenafil, alprostadil, and L-arginine. The goal is to increase local blood flow, clitoral engorgement, and sensitivity. The ExcelMale community has discussed this formulation for years; clinicians who prescribe it report consistent positive patient feedback.
One practical note: the testosterone component works best when baseline androgen levels are already in range. Women with documented androgen insufficiency may see better results after their systemic levels are corrected first. Testing free testosterone and SHBG before or alongside prescribing makes clinical sense.
Lybrido and Lybridos (Investigational)
These targeted oral combinations are designed around phenotyping women by their inhibitory profile:
- Lybrido combines sildenafil (50 mg) with testosterone (0.5 mg), targeting women with low sensitivity to sexual cues who need both CNS priming and improved genital vascular response.
- Lybridos combines buspirone (10 mg) with testosterone (0.5 mg), for women with high sexual inhibition whose primary issue is an overactive braking system.
Both remain investigational in the US. The phenotyping science behind them is well-grounded; commercial availability is the bottleneck.
Off-Label CNS Options
Bupropion and buspirone are used off-label for HSDD, particularly in women experiencing SSRI-induced sexual dysfunction. Bupropion inhibits dopamine and norepinephrine reuptake, pressing the excitatory accelerator. Clinical evidence is less robust than for flibanserin or bremelanotide, but both are widely used in psychiatric-sexual medicine practice. Lorexys -- a combination of bupropion and trazodone -- is currently under investigation as a more targeted formulation for this indication [2].
PDE5 Inhibitors
Sildenafil and tadalafil have a narrower application in women -- primarily in arousal disorders tied to diabetes or antidepressant use, where the primary problem is genital blood flow rather than central desire. The disconnect between genital engorgement and subjective desire is well-documented; improving vascular response alone does not always translate into increased desire. These agents work best when the central excitatory system is already primed but peripheral response is mechanically impaired.
Frequently Asked Questions
Can hormonal birth control affect testosterone and libido in younger women?
Yes, and this is one of the most under-discussed drivers of low desire in younger women. Combined oral contraceptives raise SHBG significantly, binding more free testosterone. Some women in their 20s test with single-digit testosterone levels as a direct result. If low libido develops after starting hormonal contraception, measuring free testosterone and SHBG is worthwhile. Switching to a progestin-only method, IUD, or non-hormonal contraception often reverses the effect.
Is testosterone safe for women with a history of breast cancer?
This is still an evolving area. Small studies suggest vaginal testosterone and vaginal DHEA are viable options for breast cancer survivors on aromatase inhibitors, since local tissue conversion does not meaningfully raise circulating estradiol. Systemic testosterone in women with hormone-receptor-positive breast cancer history requires careful discussion with the oncologist; it is not supported by major guidelines at this time, and data remain limited.
How long does treatment take to show results?
Flibanserin typically requires 4-8 weeks of consistent nightly use before effects become apparent -- it is not a situational drug. Transdermal testosterone in postmenopausal women generally shows meaningful improvement in desire and satisfying sexual events within 12-24 weeks, with continued improvement out to 52 weeks in longer trials. Local estrogen therapy for GSM often shows tissue changes within 4-8 weeks, though dyspareunia improvements can take longer.
Should women always combine medication with counseling?
Most sexual medicine specialists recommend at least brief psychosexual counseling alongside pharmacotherapy, particularly when relationship dynamics, mood disorders, or a history of trauma are part of the picture. Medication adjusts the neurochemistry; it cannot fix communication gaps or relationship dissatisfaction. The biopsychosocial model exists because biology is only one of three contributing factors. Women with situational HSDD -- present only with a specific partner or in specific contexts -- are more likely to benefit from counseling-led approaches than pharmacotherapy alone.
What should women ask their doctor before starting any of these treatments?
Four questions are worth raising: What specifically is driving my symptoms -- hormonal, structural, psychological, or a combination? Have my free testosterone and SHBG been measured, not just total testosterone? If I'm on oral estrogen, have we discussed switching to transdermal? And if the first treatment does not work after a reasonable trial, what is the next step in the clinical plan?
Related ExcelMale Forum Discussions
- Treatments That May Increase Sex Drive in Women -- An early community thread on compounded options for women's libido, including the first discussions of Scream Cream from a pharmacy compounding perspective.
- Scream Cream to Increase Sex Drive and Orgasms in Women -- Discussion of the compounded clitoral cream formulation -- ingredients, clinical feedback from prescribers, and practical application guidance.
- Testosterone and Menopause -- Every Woman Should Know This -- A comprehensive thread covering the evidence for testosterone in perimenopausal and postmenopausal women, including dosing and monitoring approaches.
- Testosterone in Women -- Myths, Benefits, and Risks of HRT After Menopause -- A deep dive with Professor Susan Davis, one of the leading global researchers on women's testosterone, covering measurement accuracy, therapeutic dosing, and common misconceptions.
- In the Search for Libido -- Started Flibanserin -- A real-world account of flibanserin use, including community discussion of the drug's modest effect size, insurance barriers, and clinical experience from members.
- Treatments for Low Libido in Men (Covering Flibanserin and Bremelanotide Context) -- Although focused primarily on men, this thread includes a thorough review of flibanserin and bremelanotide mechanisms relevant to both sexes.
Key References
- Nappi RE, Tiranini L, Martini E, et al. Medical Treatment of Female Sexual Dysfunction. Urol Clin North Am. 2022;49(2):299-307. doi:10.1016/j.ucl.2022.02.001
- Barakeh D, Mdaihly H, Karaoui LR. Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women. Ann Pharmacother. 2025;59(2):148-161. doi:10.1177/10600280241253273
- Vereecken S, Achua J, Delgado J, Casperson K. Comparative Analysis of Flibanserin, Bremelanotide, and Testosterone Therapy for Female Sexual Desire. J Sex Med. 2025;22(Supplement_4). doi:10.1093/jsxmed/qdaf320.390
- Edinoff AN, Sanders NM, Lewis KB, et al. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurol Int. 2022;14(1):49-60. doi:10.3390/neurolint14010006
- Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Sex Med. 2019;16(9):1331-1337. doi:10.1016/j.jsxm.2019.07.012
- Parish SJ, Simon JA, Davis SR, et al. ISSWSH Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867. doi:10.1016/j.jsxm.2021.01.169
- Burton CS, Mishra K. Pharmacologic therapeutic options for sexual dysfunction. Curr Opin Obstet Gynecol. 2022;34(6):402-408. doi:10.1097/GCO.0000000000000821
- Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness. Menopause. 2018;25(11):1339-1353. doi:10.1097/GME.0000000000001238
- Bezpalko L, Jagiello-Wojtowicz E, Wierzbicka A, et al. Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study. Climacteric. 2022;25(5):476-482. doi:10.1080/13697137.2022.2050208
- Laajaj N, Rais R, Lam W, et al. A Look at Hypoactive Sexual Desire Disorder in Women. J Reprod Med Gynecol Obstet. 2024. PMC12437410
Conclusion
One thing most hormonal health discussions leave out: the relationship between oral estrogen, SHBG, and testosterone suppression is probably responsible for more undiagnosed low desire in midlife women than any other single factor. A woman can be on hormone replacement, have a "normal" total testosterone result, and still have essentially no free testosterone available to her tissues -- all because the oral estrogen she is taking is driving SHBG up. Switching to transdermal estrogen costs nothing and often changes everything.
The pharmacological toolkit for female sexual dysfunction has expanded meaningfully in the past decade. The gaps are real -- no FDA-approved testosterone product for women, limited options for postmenopausal HSDD that are not off-label -- but the clinical evidence base has never been stronger. Women deserve the same level of attention to sexual health that men have received for 30 years.
For further reading, see our guides on Testosterone and Menopause and Testosterone Myths, Benefits, and Risks of HRT After Menopause.
About ExcelMale
ExcelMale.com is a men's health forum and educational resource founded by Nelson Vergel, a chemical engineer, long-term TRT patient, and author of Testosterone: A Man's Guide and Beyond Testosterone. With more than 24,000 members and 20+ years of forum archives, ExcelMale provides evidence-based information on testosterone replacement therapy, hormone optimization, sexual health, and related topics for both men and women. Nelson is a recognized patient advocate with over 34 years of personal experience on TRT.
